FDA Compounding Enforcement Could Have Been More Aggressive, Hamburg Acknowledges; Tense Hearing Continues Legislative Stalemate
This article was originally published in The Pink Sheet Daily
Executive Summary
House Republicans remain unconvinced that FDA needs additional enforcement powers as Commissioner Hamburg is grilled on why the agency didn’t employ its current forceful inspection approach in the run-up to New England Compounding Center tragedy.
You may also be interested in...
FDA Compounder Inspections May Help Set New Enforcement Standard
Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.